{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T10:18:05Z","timestamp":1786270685984,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014565","name":"Bausch Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01204-1","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T06:02:01Z","timestamp":1719295321000},"page":"1917-1928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Canadian Expert Consensus on the Use of Halobetasol Propionate\/Tazarotene Lotion for Plaque Psoriasis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9286-1534","authenticated-orcid":false,"given":"Lyn","family":"Guenther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-9050","authenticated-orcid":false,"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ron","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1718-884X","authenticated-orcid":false,"given":"Lorne E.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9719-0810","authenticated-orcid":false,"given":"Catherine","family":"Maari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6473-4586","authenticated-orcid":false,"given":"Howard","family":"Yanofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"4","key":"1204_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2310\/7750.2011.10066","volume":"15","author":"K Papp","year":"2011","unstructured":"Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210\u20139. https:\/\/doi.org\/10.2310\/7750.2011.10066.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1204_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","volume":"148","author":"S Hsu","year":"2022","unstructured":"Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2022;148(1):95\u2013102. https:\/\/doi.org\/10.1001\/archdermatol.2011.1410.","journal-title":"Arch Dermatol"},{"issue":"4","key":"1204_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2310\/7750.2010.09066","volume":"14","author":"K Papp","year":"2010","unstructured":"Papp K, Valenzuela F, Poulin Y, Bernstein G, Wasel N. Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. J Cutan Med Surg. 2010;14(4):167\u201374. https:\/\/doi.org\/10.2310\/7750.2010.09066.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1204_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-021-00518-8","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053\u201364. https:\/\/doi.org\/10.1007\/s13555-021-00518-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1204_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2020","unstructured":"Elmets CA, Korman NJ, Prater F, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020;84(2):432\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"issue":"10281","key":"1204_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"3","key":"1204_CR7","first-page":"1","volume":"22","author":"MN Nicholas","year":"2017","unstructured":"Nicholas MN, Gooderham M. Psoriasis, depression, and suicidality. Skin Ther Lett. 2017;22(3):1\u20134.","journal-title":"Skin Ther Lett"},{"issue":"4","key":"1204_CR8","doi-asserted-by":"publisher","first-page":"e027535","DOI":"10.1136\/bmjopen-2018-027535","volume":"9","author":"B Strober","year":"2019","unstructured":"Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4):e027535. https:\/\/doi.org\/10.1136\/bmjopen-2018-027535.","journal-title":"BMJ Open"},{"issue":"4","key":"1204_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.058.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1204_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1365-4632.2011.05359.x","volume":"51","author":"AR Levy","year":"2012","unstructured":"Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432\u201340. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05359.x.","journal-title":"Int J Dermatol"},{"issue":"10","key":"1204_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003\u20132011. JAMA Dermatol. 2013;149(10):1180\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5264.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1204_CR12","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe BS, Rice G, et al. The challenge of managing psoriasis: Unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504\u201313.","journal-title":"Am Health Drug Benefits"},{"key":"1204_CR13","unstructured":"Canadian Psoriasis Network. Psoriasis journey to stability. National report\u2014Canadians\u2019 journey living with psoriasis. 2018.:2\u201331. https:\/\/www.canadianpsoriasisnetwork.com\/wp-content\/uploads\/2018\/09\/JTSFinal-r.pdf. Accessed"},{"key":"1204_CR14","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278\u201385.","journal-title":"Can Fam Physician"},{"issue":"2","key":"1204_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2018.03.040","volume":"79","author":"LS Gold","year":"2018","unstructured":"Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.040.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1204_CR16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.25251\/skin.4.1.1","volume":"4","author":"L Green","year":"2020","unstructured":"Green L, Armstrong A, Teller CF, Bell S, Lin T. Treatment of psoriasis: a survey on patient preference and satisfaction. Skin J Cut Med. 2020;4(1):S1\u2013S1.","journal-title":"Skin J Cut Med"},{"key":"1204_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1729335","author":"S Segaert","year":"2020","unstructured":"Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatol Treat. 2020. https:\/\/doi.org\/10.1080\/09546634.2020.1729335.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1204_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/1203475420903682","volume":"24","author":"K Maliyar","year":"2020","unstructured":"Maliyar K, Fleming P, Ogunyemi B, Lynde C. A brief history of psoriasis management in Canada. J Cutan Med Surg. 2020;24(3):273\u20137. https:\/\/doi.org\/10.1177\/1203475420903682.","journal-title":"J Cutan Med Surg"},{"key":"1204_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/561018","volume":"2012","author":"L Uva","year":"2012","unstructured":"Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. https:\/\/doi.org\/10.1155\/2012\/561018.","journal-title":"Int J Endocrinol"},{"issue":"12","key":"1204_CR20","first-page":"1280","volume":"17","author":"E Tanghetti","year":"2018","unstructured":"Tanghetti E, Lebwohl M, Stein GL. Tazarotene revisited: safety and efficacy in plaque psoriasis and its emerging role in treatment strategy. J Drugs Dermatol. 2018;17(12):1280\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1204_CR21","first-page":"197","volume":"16","author":"JL Sugarman","year":"2017","unstructured":"Sugarman JL, Stein Gold L, Lebwohl MG, Pariser DM, Alexander BJ, Pillai R. A phase 2, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol\/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16(3):197\u2013204.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"1204_CR22","first-page":"855","volume":"17","author":"JL Sugarman","year":"2018","unstructured":"Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies. J Drugs Dermatol. 2018;17(8):855\u201361.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1204_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/jdv.17113","volume":"35","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Papp K, et al. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%\/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. J Eur Acad Dermatol. 2021;35(5):1152\u201360. https:\/\/doi.org\/10.1111\/jdv.17113.","journal-title":"J Eur Acad of Dermatol Venereol."},{"issue":"9","key":"1204_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/1060028020910439","volume":"54","author":"V Ramachandran","year":"2020","unstructured":"Ramachandran V, Bertus B, Bashyam AM, Feldman SR. Treating psoriasis with halobetasol propionate and tazarotene combination: a review of phase II and III clinical trials. Ann Pharmacother. 2020;54(9):872\u20138. https:\/\/doi.org\/10.1177\/1060028020910439.","journal-title":"Ann Pharmacother"},{"key":"1204_CR25","unstructured":"PrULTRAVATE\u00ae halobetasol propionate cream 0.05% w\/w, halobetasol propionate ointment 0.05% w\/w halobetasol propionate lotion 0.01% w\/w Product monograph including patient medication information. Bausch Health, Canada Inc.  2150 St-Elzear Blvd., West Laval, Quebec, H7L 4 A 8  Oct 7, 2020. https:\/\/bauschhealth.ca\/wp-content\/uploads\/pdf\/Ultravate%20PM-E-2020-10-07.pdf"},{"issue":"11","key":"1204_CR26","first-page":"15","volume":"11","author":"ND Bhatia","year":"2018","unstructured":"Bhatia ND, Pariser DM, Kircik L, et al. Safety and efficacy of a halobetasol 0.01%\/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream. J Clin Aesthet Dermatol. 2018;11(11):15\u20139.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4","key":"1204_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/09546634.2019.1668907","volume":"32","author":"EA Tanghetti","year":"2019","unstructured":"Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R. Optimized formulation for topical application of a fixed combination halobetasol\/tazarotene lotion using polymeric emulsion technology. J Dermatol Treat. 2019;32(4):391\u20138. https:\/\/doi.org\/10.1080\/09546634.2019.1668907.","journal-title":"J Dermatol Treat"},{"key":"1204_CR28","unstructured":"PRDUOBRII\u2122 halobetasol propionate and tazarotene lotion 0.01% w\/w halobetasol propionate and 0.045% w\/w tazarotene Product monograph including patient medication information Bausch Health, Canada Inc. 2150 St-Elzear Blvd., West Laval, Quebec, H7L 4A8 Canada. June 8, 2020. https:\/\/pdf.hres.ca\/dpd_pm\/00056991.PDF"},{"issue":"4","key":"1204_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/135581969900400410","volume":"4","author":"N Black","year":"1999","unstructured":"Black N, Murphy M, Lamping D, et al. Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy. 1999;4(4):236\u201348. https:\/\/doi.org\/10.1177\/135581969900400410.","journal-title":"J Health Serv Res Policy"},{"issue":"Suppl. 4","key":"1204_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04059.x","volume":"25","author":"G Murphy","year":"2011","unstructured":"Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol. 2011;25(Suppl. 4):3\u20138. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04059.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1204_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jaad.2018.09.002","volume":"80","author":"MG Lebwohl","year":"2019","unstructured":"Lebwohl MG, Sugarman JL, Gold LS, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.002.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1204_CR32","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s13555-021-00560-6","volume":"11","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Tanghetti EA, Stein Gold L, Del Rosso JQ, Gilyadov NK, Jacobson A. Fixed-combination halobetasol propionate and tazarotene in the treatment of psoriasis: narrative review of mechanisms of action and therapeutic benefits. Dermatol Ther. 2021;11(4):1157\u201374. https:\/\/doi.org\/10.1007\/s13555-021-00560-6.","journal-title":"Dermatol Ther"},{"issue":"8","key":"1204_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2019.06.277","volume":"18","author":"L Stein Gold","year":"2019","unstructured":"Stein Gold L, Lain E, Green LJ, Lin T, Israel R. Halobetasol 0.01%\/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy. J Drugs Dermatol. 2019;18(8):815\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.277.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"1204_CR34","first-page":"863","volume":"17","author":"L Stein Gold","year":"2018","unstructured":"Stein Gold L, Kircik LH, Pariser D, et al. Rapid onset of action in patients with moderate-to-severe plaque psoriasis with halobetasol 0.01%\/Tazarotene 0.045% fixed combination. J Drugs Dermatol. 2018;17(8):863\u20138.","journal-title":"J Drugs Dermatol"},{"key":"1204_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1914310","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Del Rosso JQ, Green L, Jacobson A. Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%\/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis. J Dermatol Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1914310.","journal-title":"J Dermatol Treat"},{"key":"1204_CR36","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.2147\/PPA.S117006","volume":"10","author":"I Belinch\u00f3n","year":"2016","unstructured":"Belinch\u00f3n I, Rivera R, Blanch C, Comellas M, Liz\u00e1n L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European union: a systematic review of the literature. Patient Prefer Adher. 2016;10:2357\u201367. https:\/\/doi.org\/10.2147\/PPA.S117006.","journal-title":"Patient Prefer Adher"},{"issue":"5","key":"1204_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/1203475416655705","volume":"20","author":"C Committee","year":"2016","unstructured":"Committee C. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009. J Cutan Med and Surg. 2016;20(5):375\u2013431. https:\/\/doi.org\/10.1177\/1203475416655705.","journal-title":"J Cutan Med and Surg"},{"issue":"5","key":"1204_CR38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/1203475418773736","volume":"22","author":"R Vender","year":"2018","unstructured":"Vender R, Gooderham MJ, Guenther LC, et al. Canadian patients\u2019 preferences in topical psoriasis care: Insights from the PROPEL surveys. J Cutan Med Surg. 2018;22(5):464\u201371. https:\/\/doi.org\/10.1177\/1203475418773736.","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"1204_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/archderm.140.4.408","volume":"140","author":"SS Zaghloul","year":"2004","unstructured":"Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408\u201314. https:\/\/doi.org\/10.1001\/archderm.140.4.408.","journal-title":"Arch Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01204-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T17:20:20Z","timestamp":1721496020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01204-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01204-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L. Guenther is on the Speaker\u2019s Bureau of, a consultant for, and\/or has received grant\/research support from Abbvie, Altana, Amgen, Aslan, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Eli Lilly and Company, Galderma, GSK, Innovaderm, Janssen, Leo Pharma, Merck Frosst, Novartis, Pfizer, Sandoz, Sun Pharma, and UCB. I. Turchin has been advisor, consultant, speaker and\/or investigator for Abbvie, Amgen, Arcutis, Aristea, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Galderma, Incyte, Janssen, Kiniksa, LEO Pharma, Mallinckrodt, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. R. Vender has received grants and\/or research support from, is on the Speaker\u2019s Bureau for, received honoraria from, and\/or is a consultant for Abbvie, Actelion, Amgen, Aralez, Arcutis, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Centocor, Cipher, Dermira, Dermavant, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, Leo, Eli Lilly and Company, Meiji, Merck, Novartis, Palladin, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB, and Viatris-Mylan. L. Albrecht is on the Speaker\u2019s Bureau of, a consultant for, and\/or has received grant\/research support or honoraria from Abbvie, Akros, Amgen, Arcutis, Avillion, Bausch Health\/Valeant, Boehringer Ingelheim, BMS, Celgene, Centocor, Cutanea, Dermavant, Dermira, Eli Lilly and Company, Galderma, Glenmark, Hoffman-La Roche, Janssen, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB, and Valeant\/Bausch Health. C. Maari has received honoraria from Bausch Health, Canada Inc. H. Yanofsky has received honoraria from Bausch Health, Canada Inc. V.H. Prajapati has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Actelion, Amgen, AnaptysBio, Apogee Therapeutics, Aralez, Arcutis, Arena, Asana, Aspen, Bausch Health\/Valeant, Boehringer Ingelheim, BMS, Celgene, Cipher, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly and Company, Galderma, GSK, Homeocan, Incyte, Janssen, LEO Pharma, Medexus, Nimbus Lakshmi, Novartis, Organon, Pediapharm, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, Tribute, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}